LKQ Earnings Preview: Analysts Diverge as Stock Sits Near Multi-Year Lows

LKQ heads into Wednesday's Q3 print having lost a quarter of its value in a month, with analysts making conflicting calls on the eve of results and short sellers sitting on their largest position in at least a year.

The most active analyst move came Monday, just two days before the release. Barclays upgraded LKQ to Overweight with a $25 target, a notable shift given the firm spent the better part of 2026 holding an Equal-Weight rating and steadily cutting its target from $34 to $25. Baird moved in the opposite direction on the same day, trimming its target from $30 to $23 while keeping its Outperform rating. Barrington Research downgraded to Market Perform last week without publishing a new target. The consensus still sits at Buy across nine analysts with a mean target of $25.79, roughly 49% above the current price of $17.25, but the gap between those two numbers reflects a stock that has fallen faster than analyst revisions can follow. JP Morgan, which holds Overweight with a $27 target set earlier this month, is the only bellwether with a recently updated figure on record.

The bull and bear cases are genuinely in tension. Bulls point to the Specialty segment's 9.4% organic sales growth and to a European network they believe is positioned to benefit as alternative parts usage rises, with management guiding for 200 basis points of EBITDA margin expansion independent of volume recovery. The valuation argument is hard to dismiss: the stock trades at a PE of 6.6x and a price-to-book below 0.65x, with an earnings yield in the 89th percentile of the universe and an EV/EBITDA of 6.3x. Bears counter that North America EBITDA has contracted in six of the past seven quarters, that European organic sales fell 4.7% as repair deferrals and rising insurance premiums reduced claims, and that the structural backdrop of fewer accidents and more total loss designations is not a cyclical problem the company can manage around.

Short interest has eased slightly from its peak. The position hit 16.4 million shares in mid-October before pulling back to 15.9 million, still 6.2% of the free float and the highest level the 30-day series shows. As noted in ORTEX's prior article on this name, the July print provides the clearest reference point: LKQ fell 14.9% on that earnings day and dropped a further 7.3% over the following five sessions. Availability in the lending market remains very loose at 728%, meaning borrow costs around 0.48% are low and there is no mechanical pressure on the short position from supply constraints. That combination keeps short sellers comfortable holding through the print. Options positioning has turned slightly more cautious since the prior note, with the put/call ratio rising to 0.19 on Monday, about 1.8 standard deviations above its 20-day average of 0.13. It remains call-heavy by historical standards, but the drift toward puts on the day of the Barclays upgrade is worth watching.

Pzena Investment Management stands out on the ownership register. The value-focused manager increased its stake to 22.9 million shares, or 9% of the class, filing an updated 13G/A on October 19 after crossing 6.1% earlier in the year. BlackRock's reported holding has also grown. Neither filing implies any activist agenda, and as with all 13D/G disclosures, the positions reflect what was last reported around the 5% threshold rather than a live count.

Wednesday's print will test whether the operational deterioration that drove the July selloff has stabilised, and whether the European margin story is progressing quickly enough to matter at current valuations.